Denali Therapeutics (DNLI) Other financing activities (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Other financing activities of $6.7 million for Q1 2026, up 1025.21% year-over-year from $595000.0 in Q1 2025, and up 107.66% quarter-over-quarter from $3.2 million in Q4 2025.
Denali Therapeutics (DNLI) Other financing activities (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Other financing activities for 10 consecutive years, with $6.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 1025.21% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $14.6 million (down 14.17% YoY), while the FY2025 annual figure was $8.5 million, down 51.35% from the prior year.
- Other financing activities rose to $6.7 million in Q1 2026 per DNLI's latest filing, from $3.2 million in the prior quarter.
- Across five years, Other financing activities topped out at $9.0 million in Q2 2023 and bottomed at -$13.1 million in Q4 2023.
- Historically, Other financing activities has averaged $2.8 million across 5 years, with a median of $3.4 million in 2022.
- Annual changes were most pronounced in 2023 — Other financing activities slumped 481.69% — and 2026, when it jumped 1025.21%.
- Denali Therapeutics' Other financing activities stood at $3.4 million in 2022, then plunged by 481.69% to -$13.1 million in 2023, then soared by 131.68% to $4.2 million in 2024, then slipped by 22.41% to $3.2 million in 2025, then surged by 107.66% to $6.7 million in 2026.
- Business Quant data shows DNLI's Other financing activities at $6.7 million in Q1 2026, $3.2 million in Q4 2025, and $583000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.01 Mn |
| Jun 30, 2026 | 15.01 Mn |
| Mar 31, 2026 | 6.70 Mn |
| Mar 31, 2026 | 6.70 Mn |
| Dec 31, 2025 | 3.22 Mn |
| Dec 31, 2025 | 3.22 Mn |
| Sep 30, 2025 | 583,000.00 |
| Sep 30, 2025 | 583,000.00 |
| Jun 30, 2025 | 4.06 Mn |
| Jun 30, 2025 | 4.06 Mn |
| Mar 31, 2025 | 595,000.00 |
| Mar 31, 2025 | 595,000.00 |
| Dec 31, 2024 | 4.16 Mn |
| Dec 31, 2024 | 4.16 Mn |
| Sep 30, 2024 | 5.46 Mn |
| Sep 30, 2024 | 5.46 Mn |
| Jun 30, 2024 | 6.76 Mn |
| Jun 30, 2024 | 6.76 Mn |
| Mar 31, 2024 | 1.02 Mn |
| Mar 31, 2024 | 1.02 Mn |